171 related articles for article (PubMed ID: 14693782)
1. Randomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closure.
Aung T; Oen FT; Wong HT; Chan YH; Khoo BK; Liu YP; Ho CL; See J; Thean LH; Viswanathan AC; Seah SK; Chew PT
Br J Ophthalmol; 2004 Jan; 88(1):88-94. PubMed ID: 14693782
[TBL] [Abstract][Full Text] [Related]
2. Effects of Brimonidine and Timolol on the Progression of Visual Field Defects in Open-angle Glaucoma: A Single-center Randomized Trial.
Yokoyama Y; Kawasaki R; Takahashi H; Maekawa S; Tsuda S; Omodaka K; Nakazawa T
J Glaucoma; 2019 Jul; 28(7):575-583. PubMed ID: 31188229
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
Krupin T; Liebmann JM; Greenfield DS; Ritch R; Gardiner S;
Am J Ophthalmol; 2011 Apr; 151(4):671-81. PubMed ID: 21257146
[TBL] [Abstract][Full Text] [Related]
4. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
5. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.
Melamed S; David R
Clin Ther; 2000 Jan; 22(1):103-11. PubMed ID: 10688394
[TBL] [Abstract][Full Text] [Related]
6. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
7. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
Schuman JS
Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotection for treatment of glaucoma in adults.
Sena DF; Lindsley K
Cochrane Database Syst Rev; 2013 Feb; 2(2):CD006539. PubMed ID: 23450569
[TBL] [Abstract][Full Text] [Related]
9. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: multicenter, open-label, observational study in Germany.
Thelen U; Buchholz P; Kimmich F
Curr Med Res Opin; 2009 Apr; 25(4):1003-9. PubMed ID: 19275517
[TBL] [Abstract][Full Text] [Related]
11. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients.
Krupin T; Liebmann JM; Greenfield DS; Rosenberg LF; Ritch R; Yang JW;
Ophthalmology; 2005 Mar; 112(3):376-85. PubMed ID: 15745762
[TBL] [Abstract][Full Text] [Related]
12. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
Katz LJ
Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients.
Chen MJ; Chou JC; Hsu WM; Liu JH
J Chin Med Assoc; 2003 May; 66(5):276-81. PubMed ID: 12908569
[TBL] [Abstract][Full Text] [Related]
14. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
Liu CJ; Ko YC; Cheng CY; Chiu AW; Chou JC; Hsu WM; Liu JH
Ophthalmology; 2002 Dec; 109(12):2241-7. PubMed ID: 12466165
[TBL] [Abstract][Full Text] [Related]
15. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I.
Javitt JC; Schiffman RM
J Glaucoma; 2000 Jun; 9(3):224-34. PubMed ID: 10877373
[TBL] [Abstract][Full Text] [Related]
16. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for visual field progression in the low-pressure glaucoma treatment study.
De Moraes CG; Liebmann JM; Greenfield DS; Gardiner SK; Ritch R; Krupin T;
Am J Ophthalmol; 2012 Oct; 154(4):702-11. PubMed ID: 22835512
[TBL] [Abstract][Full Text] [Related]
18. The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma.
Yüksel N; Altintaş O; Karabaş L; Alp B; Cağlar Y
Ophthalmologica; 1999; 213(4):228-33. PubMed ID: 10420106
[TBL] [Abstract][Full Text] [Related]
19. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma.
Konstas AG; Stewart WC; Topouzis F; Tersis I; Holmes KT; Stangos NT
Am J Ophthalmol; 2001 Jun; 131(6):729-33. PubMed ID: 11384568
[TBL] [Abstract][Full Text] [Related]
20. A short term study of the additive effect of timolol and brimonidine on intraocular pressure.
Arici MK; Sayici M; Toker M; Erdoğan H; Topalkara A
Eye (Lond); 2002 Jan; 16(1):39-43. PubMed ID: 11913886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
